• Corpus ID: 161932580

Doença de Huntington : onde estamos agora?

  title={Doença de Huntington : onde estamos agora?},
  author={Cristina Janu{\'a}rio},
Tese de doutoramento em Medicina apresentada a Faculdade de Medicina da Universidade de Coimbra 
Dietary Flavonoids in the Management of Huntington’s Disease: Mechanism and Clinical Perspective
This research presents a meta-analyses of the phytochemical properties of cannabis and its application in medicine and its role in human health, as well as some examples of applications in food safety and nutrition.
Role of Dynein Axonemal Heavy Chain 6 Gene Expression as a Possible Biomarker for Huntington’s Disease: a Translational Study
Downregulations in dynein family are confirmed in the mouse model and decreased expression of DNAH6 gene was also observed in HD patients when compared to control group and negatively correlates with the CAG expansion.


Accurate prevalence and uptake of testing for Huntington's disease
Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features
J. Neurochem. (2010) 113, 1073–1091.
Huntington's disease
Your contributions to the investigation of this tragic disorder are presented and a review of current ideas about the disease is reviewed.
The current clinical management of Huntington's disease
The pharmacological management of the various movement disorders associated with Huntington's disease, the cognitive decline and the commonly encountered behavioral disturbances are reviewed.
Altered frontostriatal coupling in pre‐manifest Huntington’s disease: effects of increasing cognitive load
The objective of this study was to test the impact of cognitive demand on prefrontal connectivity in pre‐HD individuals.
Treatment of the symptoms of Huntington's disease: Preliminary results comparing aripiprazole and tetrabenazine
Both AP and TBZ increased the Unified Huntington's Disease Rating Scale (UHDRS) chorea score in a similar way, however, AP caused less sedation and sleepiness than TBZ and was better tolerated by the patients on the trial.
Apathy is not depression in Huntington's disease.
It is found that apathy and depression are not related and are clearly distinct dimensions, whereas depression was not.
Psychopathology in Huntington's disease patients
  • R. Shiwach
  • Psychology, Medicine
    Acta psychiatrica Scandinavica
  • 1994
A retrospective study of 30 Huntington's disease families showed the minimum lifetime prevalence of depression to be 39% in the prodrome and the diagnosed disease phase of the illness, and the frequency of symptomatic schizophrenia was found to be about 9%.
Huntington’s Disease: What We Learned From the Original Essay
Accurate descriptions before and after Huntington’s essay about hereditary chorea have provided humanity to sufferers and the nidus for new discovery within the field of movement disorders.
Olanzapine for Huntington's disease: An open label study